Effect of vitamin A supplementation on immune system indices in patients with ulcerative colitis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201008184105N3

Enrollment

Registered

2010-09-16

Start date

2010-04-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Ulcerative colitis. Condition 2: Ulcerative colitis. Condition 3: Ulcerative colitis. Condition 4: Ulcerative colitis. Ulcerative (chronic) ileocolitis Ulcerative (chronic) enterocolitis Ulcerative (chronic) proctitis Ulcerative (chronic) rectosigmoiditis

Interventions

Vitamin A supplement, as injections, twice (14 days interval), 50000 IU per injection.

Treatment - Other

Vitamin A supplement, as injections, twice (14 days interval), 50000 IU per injection

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: presence of ulcerative colitis, age range 20 to 45 years, signing consent, receiving similar medications during 6 months prior to the intervention, (a Salazyny drugs: Azathioprine, sulfasalazine) Exclusion criteria: Presence of any autoimmune disease (disease, MS, lupus erythematosus), chronic exposure to any infectious disease, inflammation, diabetes or cancer, consumption of any food supplement such as multivitamin- mineral, vitamin A, zinc and vitamin D and omega-3), use any type of anti-inflammatory drugs such as NSAIDS and immunosuppressives (cyclosporine and ...), pregnancy or intention to become pregnant, any surgery during six months prior to the study, BMI more than 30

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
CD4 lymphocyte count. Timepoint: before & after (day 0 & 45). Method of measurement: flowcytometery.;Proinflammatory cytokine (IL12). Timepoint: before & after (day 0 & 45). Method of measurement: ELISA.;Acute phase protein(hs-CRP). Timepoint: before & after (day 0 & 45). Method of measurement: turbidometeric.;Anti inflammatory cytokine(IL10 & IL4). Timepoint: before & after (day 0 & 45). Method of measurement: ELISA.;Serum retinol. Timepoint: before & after (day 0 & 45). Method of measurement: HPLC.	—

Measure

Time frame

CD4 lymphocyte count. Timepoint: before & after (day 0 & 45). Method of measurement: flowcytometery.;Proinflammatory cytokine (IL12). Timepoint: before & after (day 0 & 45). Method of measurement: ELISA.;Acute phase protein(hs-CRP). Timepoint: before & after (day 0 & 45). Method of measurement: turbidometeric.;Anti inflammatory cytokine(IL10 & IL4). Timepoint: before & after (day 0 & 45). Method of measurement: ELISA.;Serum retinol. Timepoint: before & after (day 0 & 45). Method of measurement: HPLC.

—

Secondary

Measure	Time frame
Clinical symotoms. Timepoint: before & after (day 0 & 45). Method of measurement: trouvel witt index.;Food intake habits & dietary intake. Timepoint: before & after (day 0 & 45). Method of measurement: FFQ & dietary record (3 days).	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026